Connor, Clark & Lunn Investment Management Ltd. Immuno Gen, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$3.75 - $20.05 $1.93 Million - $10.3 Million	514,941 Added 130.48%	909,595 $17.2 Million
Q1 2023 May 09, 2023	BUY	$3.67 - $4.92 $1.39 Million - $1.86 Million	378,881 Added 2402.09%	394,654 $1.52 Million
Q4 2022 Feb 10, 2023	BUY	$4.55 - $6.31 $71,767 - $99,527	15,773 New	15,773 $78,000
Q1 2018 May 14, 2018	SELL	$6.7 - $12.95 $891,435 - $1.72 Million	-133,050 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$5.07 - $7.92 $674,563 - $1.05 Million	133,050	133,050 $853,000

Others Institutions Holding IMGN

# of Institutions

Shares Held

1.41M

Call Options Held

Put Options Held

View Full List

About ImmunoGen, Inc.

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

More about IMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account